Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 5/2004

01-05-2004 | Case Report

Successful treatment of B-cell prolymphocytic leukemia with monoclonal anti-CD20 antibody

Authors: Yasser Abou Mourad, Ali Taher, Aref Chehal, Ali Shamseddine

Published in: Annals of Hematology | Issue 5/2004

Login to get access

Abstract

We report a patient with B-cell prolymphocytic leukemia (PLL) who was treated successfully with the monoclonal anti-CD20 antibody (rituximab). The patient had recurrent infections due to relative neutropenia, secondary to bone marrow infiltration. After treatment with monoclonal anti-CD20 antibodies (rituximab) 375 mg/m2 weekly for 4 weeks, complete remission was obtained. It was documented by normalization of peripheral blood counts, disappearance of organomegaly, and by molecular cytogenetics-fluorescent in situ hybridization (FISH) on bone marrow cells. She remains in complete remission 8 months following the discontinuation of treatment. This is the second reported case of successful treatment of B-cell PLL with rituximab.
Literature
1.
Anderson KC, Bates MP, Slougenhoupt BL, et al. (1984) Expression of human B-cell associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 63:1424–1433PubMed
2.
Tedder TF, Engel P (1994) CD 20: a regulator of cell-cycle progression of B-lymphocytes. Immunol Today 15:450–454PubMed
3.
Reff ME, Carner K, Chambers KS, et al. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD 20. Blood 83:435–445PubMed
4.
Maloney D, Grillo-Lopez AJ, White CA, et al. (1997) IDEC C2B8 (Rituxan AB) anti-CD 20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphomas. Blood 90:2188–2195PubMed
5.
McLaughlin P, Grillo-Lopez AJ, Link BK, et al. (1998) Rituximab chimeric anti-CD 20 monoclonal antibody therapy for relapsed indolent lymphoma: half of the patients respond to a four-dose treatment program. J Clin Oncol 16:2825–2833PubMed
6.
Czuczman MS, Grillo-Lopez AJ, White CA, et al. (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD 20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268–276PubMed
7.
Vartholomatos G, Tsiara S, Christou L, et al. (1999) Rituximab (anti-CD20 monoclonal antibody) administration in a young patient with resistant B-prolymphocytic leukemia. Acta Haematol 102:94–98CrossRefPubMed
8.
Perz J, Topaly J, Fruehauf S, et al. (2002) Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia. Leuk Lymphoma 43:149–151PubMed
9.
Byrd JC, Waselenko JK, Maniatis TJ, et al. (1999) Rituximab therapy in hematologic malignancies patients with circulating blood tumor cells: association with increased infusion related side effects and rapid tumor clearance. J Clin Oncol 17:791–795PubMed
10.
J.Boye, T.Elter, A.Engert (2003) An overview of the current clinical use of the anti-CD 20 monoclonal antibody Rituximab. Ann Oncol 14:520–535CrossRefPubMed
Metadata
Title
Successful treatment of B-cell prolymphocytic leukemia with monoclonal anti-CD20 antibody
Authors
Yasser Abou Mourad
Ali Taher
Aref Chehal
Ali Shamseddine
Publication date
01-05-2004
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 5/2004
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-003-0805-z

Other articles of this Issue 5/2004

Annals of Hematology 5/2004 Go to the issue

Case Report

Abnormal depolarizing patterns in three patients with filarial infection

Case Report

Delayed hemolytic transfusion reaction due to anti-S antibody in patient with anti-Jka autoantibody and multiple alloantibodies

Original Article

Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3+ and CD4+ lymphocytes

Case Report

Remarkable response to rituximab in a patient with atypical CD20++ mantle cell lymphoma of the bone marrow leading to severe pancytopenia

Original Article

A comparative study of adverse reactions occurring after administration of glycosylated granulocyte colony stimulating factor and/or dexamethasone for mobilization of neutrophils in healthy donors

Case Report

Splenic marginal zone lymphoma presenting as myelofibrosis associated with bone marrow involvement of lymphoma cells which secrete a large amount of TGF-β
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits